In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands

T. H. Kramer, P. Davis, Victor J Hruby, T. F. Burks, Frank Porreca

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The purpose of these investigations was to estimate the relative potency, receptor affinity, and agonist efficacy of several selective delta opioid agonist peptides of diverse structure, including cyclic [D-Pen2,D- Pen5]enkephalin and its p-Phe4 halogen-substituted analogs, [D-Ser2-O- tBu,Leu5,Thr6]enkephalin. Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II) in functional bioassays. The mouse-isolated vas deferens (MVD) and guinea pig-isolated ileum longitudinal muscle/myenteric plexus bioassay preparations were used; selectivity for delta opioid receptors was quantified by the relative agonist activity of the various peptides in the guinea pig-isolated ileum and MVD assays; agonist affinity and efficacy were determined using the technique of partial irreversible receptor inactivation in the MVD. Data from these experiments were analyzed both by the traditional null method and by use of the operational model of pharmacologic agonism; a comparison of these two methods, which were found to be similar, was performed. Potency determinations in MVD for the various peptides essentially matched those determined in other investigations; the relative affinity of the peptides correlated with the results of radioligand binding studies performed in other laboratories. The relative efficacies of the peptides studied were indistinguishable except for the peptide deltorphin I, which demonstrated efficacy several-fold lower than the remaining seven. All peptides were sufficiently efficacious to appear as full agonists under control conditions. These results suggest that the principle factor determining increases in potency of novel delta receptor ligands to date is an increase in receptor affinity. Efficacy should be incorporated as a drug design consideration for delta opioid agonists.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume266
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

delta Opioid Receptor
Vas Deferens
Ligands
Peptides
Ileum
Biological Assay
Guinea Pigs
D-Penicillamine (2,5)-Enkephalin
Myenteric Plexus
Halogens
Opioid Peptides
Enkephalins
Drug Design
Opioid Analgesics
In Vitro Techniques
Muscles
Ala(2)-deltorphin I

ASJC Scopus subject areas

  • Pharmacology

Cite this

In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. / Kramer, T. H.; Davis, P.; Hruby, Victor J; Burks, T. F.; Porreca, Frank.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 266, No. 2, 1993, p. 577-584.

Research output: Contribution to journalArticle

@article{da15d0b3a05d4c4b82cfcc7f541fe77a,
title = "In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands",
abstract = "The purpose of these investigations was to estimate the relative potency, receptor affinity, and agonist efficacy of several selective delta opioid agonist peptides of diverse structure, including cyclic [D-Pen2,D- Pen5]enkephalin and its p-Phe4 halogen-substituted analogs, [D-Ser2-O- tBu,Leu5,Thr6]enkephalin. Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II) in functional bioassays. The mouse-isolated vas deferens (MVD) and guinea pig-isolated ileum longitudinal muscle/myenteric plexus bioassay preparations were used; selectivity for delta opioid receptors was quantified by the relative agonist activity of the various peptides in the guinea pig-isolated ileum and MVD assays; agonist affinity and efficacy were determined using the technique of partial irreversible receptor inactivation in the MVD. Data from these experiments were analyzed both by the traditional null method and by use of the operational model of pharmacologic agonism; a comparison of these two methods, which were found to be similar, was performed. Potency determinations in MVD for the various peptides essentially matched those determined in other investigations; the relative affinity of the peptides correlated with the results of radioligand binding studies performed in other laboratories. The relative efficacies of the peptides studied were indistinguishable except for the peptide deltorphin I, which demonstrated efficacy several-fold lower than the remaining seven. All peptides were sufficiently efficacious to appear as full agonists under control conditions. These results suggest that the principle factor determining increases in potency of novel delta receptor ligands to date is an increase in receptor affinity. Efficacy should be incorporated as a drug design consideration for delta opioid agonists.",
author = "Kramer, {T. H.} and P. Davis and Hruby, {Victor J} and Burks, {T. F.} and Frank Porreca",
year = "1993",
language = "English (US)",
volume = "266",
pages = "577--584",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands

AU - Kramer, T. H.

AU - Davis, P.

AU - Hruby, Victor J

AU - Burks, T. F.

AU - Porreca, Frank

PY - 1993

Y1 - 1993

N2 - The purpose of these investigations was to estimate the relative potency, receptor affinity, and agonist efficacy of several selective delta opioid agonist peptides of diverse structure, including cyclic [D-Pen2,D- Pen5]enkephalin and its p-Phe4 halogen-substituted analogs, [D-Ser2-O- tBu,Leu5,Thr6]enkephalin. Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II) in functional bioassays. The mouse-isolated vas deferens (MVD) and guinea pig-isolated ileum longitudinal muscle/myenteric plexus bioassay preparations were used; selectivity for delta opioid receptors was quantified by the relative agonist activity of the various peptides in the guinea pig-isolated ileum and MVD assays; agonist affinity and efficacy were determined using the technique of partial irreversible receptor inactivation in the MVD. Data from these experiments were analyzed both by the traditional null method and by use of the operational model of pharmacologic agonism; a comparison of these two methods, which were found to be similar, was performed. Potency determinations in MVD for the various peptides essentially matched those determined in other investigations; the relative affinity of the peptides correlated with the results of radioligand binding studies performed in other laboratories. The relative efficacies of the peptides studied were indistinguishable except for the peptide deltorphin I, which demonstrated efficacy several-fold lower than the remaining seven. All peptides were sufficiently efficacious to appear as full agonists under control conditions. These results suggest that the principle factor determining increases in potency of novel delta receptor ligands to date is an increase in receptor affinity. Efficacy should be incorporated as a drug design consideration for delta opioid agonists.

AB - The purpose of these investigations was to estimate the relative potency, receptor affinity, and agonist efficacy of several selective delta opioid agonist peptides of diverse structure, including cyclic [D-Pen2,D- Pen5]enkephalin and its p-Phe4 halogen-substituted analogs, [D-Ser2-O- tBu,Leu5,Thr6]enkephalin. Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH2 (deltorphin I) and Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 (deltorphin II) in functional bioassays. The mouse-isolated vas deferens (MVD) and guinea pig-isolated ileum longitudinal muscle/myenteric plexus bioassay preparations were used; selectivity for delta opioid receptors was quantified by the relative agonist activity of the various peptides in the guinea pig-isolated ileum and MVD assays; agonist affinity and efficacy were determined using the technique of partial irreversible receptor inactivation in the MVD. Data from these experiments were analyzed both by the traditional null method and by use of the operational model of pharmacologic agonism; a comparison of these two methods, which were found to be similar, was performed. Potency determinations in MVD for the various peptides essentially matched those determined in other investigations; the relative affinity of the peptides correlated with the results of radioligand binding studies performed in other laboratories. The relative efficacies of the peptides studied were indistinguishable except for the peptide deltorphin I, which demonstrated efficacy several-fold lower than the remaining seven. All peptides were sufficiently efficacious to appear as full agonists under control conditions. These results suggest that the principle factor determining increases in potency of novel delta receptor ligands to date is an increase in receptor affinity. Efficacy should be incorporated as a drug design consideration for delta opioid agonists.

UR - http://www.scopus.com/inward/record.url?scp=0027485085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027485085&partnerID=8YFLogxK

M3 - Article

C2 - 8394911

AN - SCOPUS:0027485085

VL - 266

SP - 577

EP - 584

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -